Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

WEHI-539 hydrochloride

WEHI-539 hydrochloride is a selective inhibitor of Bcl-XL with an IC50 of 1.1 nM.

Product Specifications

CAS Number

[2070018-33-4]

UNSPSC

12352005

Target

Bcl-2 Family

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/WEHI-539-hydrochloride.html

Purity

99.72

Solubility

DMSO : 16.67 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

OC(C1=C(CCCOC2=CC=C(CN)C=C2)SC(C3=CC4=C(CCC/C4=N\NC5=NC(C=CC=C6)=C6S5)C=C3)=N1)=O.[H]Cl

Molecular Formula

C31H30ClN5O3S2

Molecular Weight

620.18

References & Citations

[1]Lessene G, et al. Structure-guided design of a selective BCL-X (L) inhibitor. Nat Chem Biol. 2013 Jun;9 (6) :390-7.|[2]Abed MN, et al. Antagonism of Bcl-XL is necessary for synergy between NSC 241240 and BH3 mimetics in ovarian cancer cells. J Ovarian Res. 2016 Apr 14;9:25.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

Bcl-xL

Citation 01

Acta Pharmacol Sin. 2024 Nov;45 (11) :2420-2431.|bioRxiv. 2023 Aug 5.|Blood. 2014 Dec 4;124 (24) :3587-96. |Cell Death Dis. 2018 Jan 19;9 (2) :42.|Cell Rep. 2023 Mar 30;42 (4) :112324.|Cell. 2014 Dec 18;159 (7) :1549-62.|Immunity. 2024 Jun 11;57 (6) :1289-1305.e9.|Int J Cancer. 2018 Feb 1;142 (3) :584-596.|Malays Appl Biol. (2020) 49 (1) : 193-197.|Methods Mol Biol. 2018:1711:351-398.|Mol Cancer Ther. 2025 Jul 10.|Nat Biotechnol. 2018 Feb;36 (2) :179-189.|Nat Cancer. 2024 Jul;5 (7) :1082-1101.|Nat Chem Biol. 2022 Jun;18 (6) :615-624.|Nature. 2017 Nov 9;551 (7679) :247-250. |Oncotarget. 2018 May 25;9 (40) :26046-26063.|The Department of Medical Sciences, Harvard University. 2019 Dec.|Am J Cancer Res. 2019 Dec 1;9 (12) :2580-2598.|Breast Cancer Res Treat. 2019 Feb;173 (3) :585-596.|Cancer Biology. 2020 May.|Cell Death Differ. 2014 Jul;21 (7) :1170-7. |Cell Death Differ. 2017 Jan;24 (1) :111-119. |Cell Death Dis. 2017 Dec 13;8 (12) :3216.|Cell Death Dis. 2023 Oct 28;14 (10) :705.|Cell. 2014 Dec 18;159 (7) :1549-62.|Clin Cancer Res. 2019 Dec 1;25 (23) :7139-7150. |J Ovarian Res. 2016 Apr 14;9 (1) :25. |Nat Commun. 2016 Mar 9;7:10916.|Nature. 2017 Nov 9;551 (7679) :247-250. |Oncol Rep. 2019 Dec;42 (6) :2416-2425.|Pharmacol Res. 2023 Jan:187:106628.

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

Mouse High Sensitivity C-Reactive Protein ELISA Kit
MBS026987-01 48 Well

Mouse High Sensitivity C-Reactive Protein ELISA Kit

Ask
View Details
Mouse High Sensitivity C-Reactive Protein ELISA Kit
MBS026987-02 96 Well

Mouse High Sensitivity C-Reactive Protein ELISA Kit

Ask
View Details
Mouse High Sensitivity C-Reactive Protein ELISA Kit
MBS026987-03 5x 96 Well

Mouse High Sensitivity C-Reactive Protein ELISA Kit

Ask
View Details
Mouse High Sensitivity C-Reactive Protein ELISA Kit
MBS026987-04 10x 96 Well

Mouse High Sensitivity C-Reactive Protein ELISA Kit

Ask
View Details
Recombinant Human TUBB3
RPF11528-01 50 µg

Recombinant Human TUBB3

Ask
View Details
Recombinant Human TUBB3
RPF11528-02 200 µg

Recombinant Human TUBB3

Ask
View Details